Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
Cumberland Pharmaceuticals (CPIX) reported third-quarter 2026 net income of $77.8 million, including a gain from selling its commercial business to Apotex Health. The transaction closed July 1, 2026, providing $100 million at closing and shifting Cumberland toward drug development. Quarterly revenue was $2,156,356 versus $171,821 a year earlier; the continuing-operations loss narrowed to $1,122,071 from $2,730,638. Cash totaled $80,581,021 at September 30.
Cumberland plans to submit an application for FDA approval of ifetroban for Duchenne muscular dystrophy heart disease; the FDA granted rolling review, allowing sections to be reviewed before the full application is filed. Phase 2 data showed a 5.4 percentage point improvement in heart pumping function versus a combined control group. Its systemic sclerosis trial reported no serious adverse events assessed as treatment-related; further development awaits additional evaluations.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third-quarter 2026 financial results and a company update after market close on November 10, 2026. A conference call to discuss the results and update will begin at 4:30 p.m. Eastern Time that day. A replay will be available for one year through the company's Investor Relations website.
Cumberland Pharmaceuticals (CPIX) plans to submit a New Drug Application for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). FDA granted rolling review, allowing completed sections to be reviewed before the full application is submitted. Cumberland proposes its Phase 2 FIGHT DMD trial, combined with two natural history databases, as pivotal evidence for Traditional Approval.
The 12-month trial showed a 5.4% absolute improvement in left ventricular ejection fraction, a measure of heart pumping function, with high-dose ifetroban versus a combined placebo and matched natural history control group (p=0.002). FDA suggested a Phase 3 trial and raised concerns about substantial evidence of efficacy, the endpoint, comparators, statistical planning and missing data. Cumberland will provide additional analyses. Cardiac MRI data from Months 24 and 36 of the ongoing extension are being analyzed for the application.
Cumberland Pharmaceuticals (CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis. In the 12-month pilot trial, ifetroban was generally well tolerated. No serious adverse event was assessed by the medical monitor as related to study drug. Gastrointestinal adverse events were more frequent with ifetroban than placebo; most were mild and resolved. Bleeding-related adverse events increased modestly and were predominantly mild.
Efficacy conclusions cannot be drawn because of the sample size and exploratory analysis; the trial was not designed or powered to evaluate efficacy. Limited disease progression in both groups also reduced its ability to detect a treatment difference. Cumberland plans to submit the clinical study report to the FDA and complete biomarker and extension-study cardiac imaging evaluations to inform further development decisions.
Cumberland Pharmaceuticals (CPIX) provided an updated webcast registration link for its October 26, 2026 call on the ifetroban DMD program. The webcast and conference call will begin at 4:30 p.m. Eastern Time and cover ifetroban's development as a potential treatment for cardiomyopathy, a heart muscle condition, associated with Duchenne muscular dystrophy. Webcast participants can view accompanying slides; conference-call access is audio only. A presentation copy will be available on the company's Investor Relations website.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will hold a national webcast and conference call on October 26 to update its ifetroban DMD program. The event begins at 4:30 p.m. Eastern Time and will cover the product candidate's development as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD), a condition affecting the heart muscle.
Webcast participants can view accompanying slides, while the conference call offers audio-only access. A copy of the presentation will be available on Cumberland's Investor Relations website.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results alongside the closing of a $100 million Strategic Transaction with Apotex Health, plus $11 million for inventory and transition services. Apotex acquired Cumberland’s portfolio of FDA-approved brands and related commercial organization, while Cumberland retained its late-stage development pipeline and majority stake in Cumberland Emerging Technologies.
The company’s board declared a $1.50 per share special cash dividend, paid July 31, 2026. Cumberland is transitioning to a development-stage biopharmaceutical model focused on four Phase 2 ifetroban programs, including Duchenne muscular dystrophy and cancer metastasis. For Q2 2026, loss from continuing operations was $3.1 million, with a total net loss of $4.1 million. As of June 30, 2026, Cumberland reported $62.9 million in total assets, $45.8 million in total liabilities, and $17.1 million in total equity, and it retired its $5.2 million bank line of credit.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its Q2 2026 financial results and a broader company update after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day, with replay available for one year.
Cumberland describes itself as a Tennessee-based biopharmaceutical company focused on innovative treatments for rare diseases. According to the company, its late-stage Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share on its common stock, payable on July 31, 2026 to shareholders of record on July 10, 2026. The move follows a strategic transaction with Apotex Health, under which Cumberland received $100 million in cash plus up to $11 million in additional potential payments.
The board also authorized an open-market share repurchase program of up to $5 million and noted that several directors plan new share purchase plans. Cumberland will focus resources on developing ifetroban across multiple Phase II programs targeting rare and serious diseases, while retaining significant liquidity and its majority stake in Cumberland Emerging Technologies.
Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026 to shareholders of record on July 23, 2026. The move follows a Strategic Transaction with Apotex Health, through which Cumberland received $100 million in cash and may receive up to $11 million more for inventory and transition services.
The Board also authorized an open-market share repurchase program of up to $5 million and several Board members plan additional share purchases. Cumberland will focus resources on developing ifetroban across multiple Phase 2 programs in rare and progressive diseases. The release also corrects prior references to the record date.